Brief: Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test
02/04/2025 13:00
April 2 (Reuters) - Revvity Inc RVTY.N: REVVITY SECURES FDA APPROVAL FOR IMPROVED AUTOMATED LATENT TUBERCULOSIS TEST Source text: ID:nBw3KhHX2a Further company coverage: RVTY.N (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Revvity
See all newsBrief: Revvity Launches Signals Labgistics Solution To Connect And Orchestrate Scientific Workflows
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT